ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
25 févr. 2021 07h00 HE
|
ProQR Therapeutics N.V.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from...